Pharmion (PHRM) Shareholders Approve Acquisition by Celgene (CELG)
Celgene Corporation (NASDAQ: CELG) and Pharmion Corporation (NASDAQ: PHRM) announced that Pharmion’s shareholders approved the acquisition of Pharmion by Celgene. The companies anticipate the closing of the acquisition will occur on Friday, March 7, 2008.
The transaction will bring together three medically therapies, Revlimid, Thalomid and Vidaza. These products are expected to generate multiple global revenue streams for accelerated financial growth over the next five years and beyond. Additionally, the combined company’s pipeline will be positioned to advance promising clinical research in hematology, as well as solid tumor cancers and inflammation.
Celgene Corporation is an integrated biopharmaceutical company.[SM]
The transaction will bring together three medically therapies, Revlimid, Thalomid and Vidaza. These products are expected to generate multiple global revenue streams for accelerated financial growth over the next five years and beyond. Additionally, the combined company’s pipeline will be positioned to advance promising clinical research in hematology, as well as solid tumor cancers and inflammation.
Celgene Corporation is an integrated biopharmaceutical company.[SM]
You May Also Be Interested In
- UPDATE: RR Donnelley (RRD) to Buy Edgar Online (EDGR) for $70.5M
- Nomura Securities Maintains a 'Buy' on SAP AG (SAP); Scooping Up Ariba
- Monsanto (MON) to Buy Precision Planting for $210M in Cash, $40M in Performance-Based Payment
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
